Document is current
Any future updates will be listed below
-
Authors
Mora, Jaume https://orcid.org/0000-0002-9386-5980
Chan, Godfrey C. F.
Morgenstern, Daniel A. https://orcid.org/0000-0002-4859-1108
Amoroso, Loredana
Nysom, Karsten https://orcid.org/0000-0003-2935-0058
Faber, Jörg
Wingerter, Arthur
Bear, Melissa K.
Rubio-San-Simon, Alba
de Las Heras, Blanca Martínez
Tornøe, Karen
Düring, Maria
Kushner, Brian H.
- License Information
-
More Information
Article History
Received: 19 January 2024
Accepted: 20 January 2025
First Online: 14 February 2025
Competing interests
: J.M. has received consulting fees from Y-mAbs Therapeutics, Inc. D.A.M. has been a member of advisory boards/consultant for Clarity Pharmaceuticals, EUSA Pharma, Oncoheroes Biosciences, RayzeBio, Inc., Regeneron, US WorldMeds, and Y-mAbs Therapeutics, Inc.; has received speaker fees from Takeda Israel and Y-mAbs Therapeutics, Inc.; and received travel expenses from AbbVie. L.A. has been a member of an advisory board for Recordati (EUSA Pharma). K.N. has been a member of advisory boards/consultant for Bayer AG, EUSA Pharma, and Y-mAbs Therapeutics, Inc.; has performed teaching for Bayer AG and Y-mAbs Therapeutics, Inc.; and is a member of a Data Monitoring Committee for Lilly. J.F. has coordinated PI and participation in a compassionate use program for Y-mAbs Therapeutics, Inc. A.W. has been an advisory board member for EUSA Pharma and Y-mAbs Therapeutics, Inc.; and has received expenses for congress attendance from Y-mAbs Therapeutics, Inc. M.K.B. has received consulting fees from Y-mAbs Therapeutics, Inc. A.R.S.S. has been an advisory board member for, and has received expenses for congress attendance from, EUSA Pharma. K.T. and M.D. are employed by, and hold equity with, Y-mAbs Therapeutics, Inc. The remaining authors declare no competing interests.
